[A12-07] Ipilimumab - Benefit assessment according to § 35a Social Code Book V (dossier assessment)
Last updated 02.05.2012
Project no.:
A12-07
Commission:
Commission awarded on 31.01.2012 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer, Skin and hair
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A19-12 | Ipilimumab (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A18-44 | Ipilimumab (melanoma) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A18-12 | Ipilimumab (melanoma) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A13-44 | Ipilimumab (new therapeutic indication) - Benefit assessment according to § 35a Social Code Book V (dossier assessment) | Commission completed |
| A11-16 | Ipilimumab - Consultation on content and completeness of the dossier | Commission completed |
| A20-116 | Ipilimumab (non-small cell lung cancer, combination with nivolumab) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2012-08-02 A G-BA decision was published.